OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma

May 13th 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

Dr. Ross on the Utility of First- and Second-Generation EGFR Inhibitors in EGFR-Mutant NSCLC

May 13th 2021

Helen J. Ross, MD, discusses the utility of first- and second-generation EGFR inhibitors in EGFR-mutant non–small cell lung cancer.

Dr. Morganstein on the Mechanism of Action of Lurbinectedin in Metastatic SCLC

May 13th 2021

Neil Morganstein, MD, discusses the mechanism of action of lurbinectedin in metastatic small cell lung cancer.

Dr. Garassino on Safety Protocols for Patients With Cancer in Italy During COVID-19

May 13th 2021

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

Dr. Sonpavde on Anticipated Data in Bladder Cancer

May 12th 2021

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

Dr. Rapisuwon on Clinical Trial Barriers in the United States in Mucosal Melanoma

May 12th 2021

Suthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12th 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRC

May 12th 2021

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Dr. Gatti-Mays on Selecting Between FDA-Approved Assays for PD-L1 Expression in Breast Cancer

May 11th 2021

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

Dr. Lavery on the Decline in Esophageal Cancer Diagnoses in Ireland During COVID-19

May 11th 2021

Anita Lavery, MD, MRCP, discusses the decline in esophageal cancer diagnoses in Ireland during the COVID-19 pandemic.

Dr. Alkharabsheh on Remaining Challenges in High-Risk CLL

May 11th 2021

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Wesolowski on the Potential Future Utility of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 10th 2021

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis

May 10th 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dr. Kazandjian on Novel Therapeutic Targets in Multiple Myeloma

May 10th 2021

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Dr. Zhu on Stratifying Treatments in Node-Positive Prostate Cancer

May 10th 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

May 8th 2021

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

May 7th 2021

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.